Trial to Evaluate Safety, Tolerability, and Parmacokinetics of ALN-TTR02 in Healthy Volunteer Subjects

NCT01559077 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

INDUSTRY

Sponsor class

Conditions

TTR-mediated Amyloidosis

Interventions

DRUG: ALN-TTR02
DRUG: Sterile Normal Saline (0.9% NaCl)

Sponsor

Alnylam Pharmaceuticals